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ABSTRACT
While most myelodysplastic syndrome/acute myeloid leukemia cases are sporadic, rare familial cases occur and provide insight into leukemogenesis. The most clearly defined familial cases result from inherited mutations in RUNX1 or CEBPA. Recently, novel germline mutations in GATA2 were reported. We thus investigated individuals from families with ≥ 1 first-degree relative with myelodysplastic syndrome/acute myeloid leukemia with wildtype RUNX1 and CEBPA, for GATA2 mutations. Screening for other recurrent mutations was also performed. A GATA2 p.Thr354Met mutation was observed in a pedigree in which 2 first-degree cousins developed high risk myelodysplastic syndrome with monosomy 7. They were also noted to have acquired identical somatic ASXL1 mutations and both died despite stem cell transplantation. These findings confirm that germline GATA2 mutations predispose to familial myelodysplastic syndrome/acute myeloid leukemia and that monosomy 7 and ASXL1 mutations may be recurrent secondary genetic abnormalities triggering overt malignancy in these families.
Key words: familial, MDS, GATA2, monosomy 7. (6) (7) (8) . In many of these pedigrees, the GA TA 2 mutation acts as a predisposing rather than initiating mutation with many carriers remaining asymptomatic.
Herein, we present a novel pedigree with germline GATA2 mutation in which 2 affected individuals presented with MDS/AML with monosomy 7, and also had identical somatic ASXL1 mutations. We hypothesize that the nature of the secondary genetic events observed in GATA2-mutated individuals may explain the clinical heterogeneity observed within and between pedigrees.
DESIGN AND METHODS
Study design and patient selection
Individuals from 5 families with ≥ 1 first-degree relative with MDS/AML were collected for investigation after exclusion of RUNX1 and CEBPA mutations (9) . Ethics approval (06/Q0401/31) was received and informed consent was obtained according to the Declaration of Helsinki.
Mutation analysis
Genomic DNA was extracted from peripheral blood or bone marrow aspirate mononuclear cells using phenol and chloroform, following standard procedures. DNA was obtained from saliva using a commercially available collection tube (Oragene, Ottawa, Canada) and following product instructions. Primers used for PCR amplification of the entire coding region of GA TA 2 (exons 2-6) are listed in Supplementary Table 1. The amplified regions and primer sequences for RUNX 1, CEBPA , NPM1 and FLT3 are also summarized in Supplementary Table 1 . A SX L1, TET2 and c-CBL genes were PCR amplified as described previously (10) (11) (12) . Sequence analysis was carried out by bidirectional sequencing of the purified PCR products using an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, USA). The obtained sequences were compared to the corresponding germline gene and protein sequences (accession numbers for GATA2: NM_032638.4 and NP_116027.2; for ASXL1: NM_015338.5 and NP_056153.2) available in the National Center for Biotechnology Information (NCBI) GenBank database. All mutations were confirmed from 2 independent PCR amplicons.
RESULTS AND DISCUSSION
Five individuals in a single pedigree ( Figure 1 ) were noted to have GATA2 mutations with the same GATA2 p.Thr354Met (c.1061C>T) mutation (Figure 2A ) detected in all 5 individuals (III-5, III-7, IV-1, IV-6, IV-10). The mutation was detected in the disease and the available remission sample of IV-6, suggesting a germline mutation.
Confirmatory germline DNA was not available from the deceased individuals; however, a germline mutation was confirmed in the salivary DNA of III-7. A somatic ASXL1 p.Gly646TrpfsX12 (c.1934dupG) frameshift mutation ( Figure 2B ) was noted in the MDS/AML sample from IV-1 and IV-6 but was lacking from the remission sample of IV-6 suggesting an identical acquired ASXL1 mutation. No additional mutations were detected in the other screened genes.
Pedigree
The proband IV-6, presented at age 23 with symptomatic cytopenias and no significant III-5 and III-7 were confirmed as obligate carriers of GATA2 mutation. IV-9 was screened as a potential allogeneic sibling donor for IV-10 and had wildtype GATA2. IV-7
and IV-8 were screened for the mutation but had wildtype GATA2. No DNA was available from other family members however genetic counseling and testing is ongoing.
The family history was also notable for the paternal grandmother (II-2) of the proband (IV-6) having died of AML as well as his paternal great-uncle (II-3) and greatgrandmother (I-2) also reported to have died of "leukemia". To date, the parental generation has remained well with the obligate carriers (III-1, III-5 and III-7) having no history of hematological illness nor of recurrent infections (despite being 60, 52 and 51 years respectively). are among the most common mutations observed in de novo MDS patients at 11-20% and are associated with an adverse prognostic outcome (12, 13, 19, 20) . The presence of the identical somatic heterozygous ASXL1 mutation in both affected members of our pedigree suggests that ASXL1 mutations may represent an important trigger for the development of overt disease in GATA2-mutated patients. Although some authors have proposed that the p.Gly646TrpfsX12 mutation may be a PCR artifact, this mutation was not detected in the remission sample, nor in the obligate carriers in our pedigree, nor previously in a series of healthy adults (20) , confirming that it is an acquired mutation in
MDS.
Identifying germline mutations in patients with MDS is not only important for the purpose of delineating pathogenetic mechanisms, but also has significant implications for clinical practice, particularly in donor selection for allogeneic HSCT. A recent report described 6 patients with GATA2 deficiency who underwent allogeneic HSCT for their disease (21) . Two related, 2 unrelated and 2 cord blood HSCTs were described with excellent outcomes in all but the sickest patient (who was transplanted while infected and 9 on a ventilator). Only the patient who received a single umbilical cord blood graft had delayed engraftment. The results from our family are poorer with both individuals dying post allogeneic HSCT, one from early infectious complications and one from relapsed MDS. However, these individuals were transplanted several years ago and underwent a myeloablative conditioning with less than ideal donors whereas the Cuellar-Rodriguez report used a non-myeloablative regimen with better matched stem cell donors. It is also possible that ASXL1 mutations predict for poorer outcomes in GA TA 2 mutated patients and explain the poor results noted in our pedigree. Regardless, the recently reported successful HSCT results are encouraging, particularly as this therapy is currently the only potentially curative treatment for MDS (21) . The decision of when to consider allogeneic stem cell transplantation in individuals with GATA2 mutations remains unclear, especially in the case of IV-10 who already has significant neutropenia and monocytopenia, as well as III-5 and III-7 who have confirmed GATA2 mutations without hematological abnormality. Thus prognostic factors, which help identify GATA2-mutated patients at high risk of developing MDS/AML, would be particularly helpful.
Given the increased recognition of familial MDS, many modern cases are being discovered as siblings are investigated as potential HSCT donors in an affected family.
Frequently, a comprehensive workup only occurs if the potential donor is discovered to have peripheral blood count abnormalities. This screening may not be sufficient as many patients with inherited GATA2, RUNX1 or CEBPA mutations have normal hematological parameters. Therefore, testing for GATA2 mutations should be considered prior to sibling-donor allogeneic HSCT in all young patients with MDS.
In conclusion, we present a case of inherited GA TA 2 mutation causing early onset familial MDS in which no antecedent hematological abnormalities or immunodeficiency were noted other than a vague history of infections, suggesting that inherited GA TA 2 mutations may be difficult or impossible to detect without genetic screening in some families. This lack of prior hematological or immune abnormalities is particularly important in the setting of allogeneic HSCT when a sibling donor is being considered.
Additionally, the acquisition of ASXL1 mutations and monosomy 7, detected in both 
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